In this study, we demonstrated the biological role of MIR29A in comprehensively inhibiting LOX, LOXL2, and VEGFA and its effect on counteracting metastatic behaviors by inducing apoptosis and repressing cell viability and wound healing performance, indicating the potential of MIR29A as an adjuvant therapy that may further enhance the treatment effectiveness of the targeting therapy for HCC. The gene discussed is LOXL2; the disease is hepatocellular carcinoma.